The mechanism: CMS's Medicare GLP-1 Bridge went live July 1, 2026, capping beneficiary cost-sharing at $50 a month for eligible Part D enrollees, and the companion BALANCE model lets state Medicaid programs sign on through January 2027 to get supplemental manufacturer rebates on top of standard Medicaid Drug Rebate Program discounts. Both mechanisms do the same thing: they turn GLP-1s from a narrow, prior-authorization-gated diabetes benefit into a government-subsidized, formulary-negotiated weight-management benefit at scale. That's a switch that moves tens of billions in drug spend through the system every year, and it hits two very different parts of the same balance sheet.
Here's the wrinkle almost nobody prices in: PBMs and insurers usually move together, because most of the biggest ones are the same company. Not this time. The PBM side negotiates the rebate — bigger volume, more competing GLP-1 entrants (Wegovy, Zepbound, and now oral options like Lilly's Foundayo), more formulary leverage, and PBMs keep a cut of the spread even as list prices stay high. The insurer side has to actually pay the claim, and GLP-1s are famously sticky, chronic, expensive fills that go straight into medical/pharmacy loss ratio math with no offsetting premium bump until the next rate cycle.